Market cap
$211 Mln
Recently Viewed
Clear AllMarket cap
$211 Mln
Revenue (TTM)
$26 Mln
P/E Ratio
--
P/B Ratio
2.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-56 Mln
ROE
-1.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.2
Debt to Equity
1.1
Book Value
$--
EPS
$-0.4
Face value
--
Shares outstanding
205,246,000
CFO
$-613.42 Mln
EBITDA
$-768.46 Mln
Net Profit
$-981.61 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Spectrum Pharmaceuticals (SPPI)
| 178.4 | 4.0 | -6.4 | 17.0 | -31.2 | -45.1 | -19.0 |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Spectrum Pharmaceuticals (SPPI)
| -70.9 | -62.8 | -6.3 | -58.4 | -53.6 | 327.8 | -26.5 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The... company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. As of July 31, 2023, Spectrum Pharmaceuticals, Inc. operates as a subsidiary of Assertio Holdings, Inc. Read more
Pres, CEO & Director
Mr. Thomas J. Riga
Pres, CEO & Director
Mr. Thomas J. Riga
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Spectrum Pharmaceuticals Inc (SPPI) is $1.03 (NASDAQ) as of 04-Aug-2023 09:30 EDT. Spectrum Pharmaceuticals Inc (SPPI) has given a return of -31.18% in the last 3 years.
Since, TTM earnings of Spectrum Pharmaceuticals Inc (SPPI) is negative, P/E ratio is not available.
The P/B ratio of Spectrum Pharmaceuticals Inc (SPPI) is 2.40 times as on 04-Aug-2023, a 46 discount to its peers’ median range of 4.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.87
|
2.43
|
|
2021
|
-1.24
|
4.13
|
|
2020
|
-2.82
|
3.59
|
|
2019
|
-2.99
|
2.13
|
|
2018
|
-7.70
|
3.26
|
The 52-week high and low of Spectrum Pharmaceuticals Inc (SPPI) are Rs -- and Rs -- as of 27-Apr-2026.
Spectrum Pharmaceuticals Inc (SPPI) has a market capitalisation of $ 211 Mln as on 04-Aug-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Spectrum Pharmaceuticals Inc (SPPI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.